PMID- 31721026 OWN - NLM STAT- MEDLINE DCOM- 20210322 LR - 20210322 IS - 1179-187X (Electronic) IS - 1175-3277 (Print) IS - 1175-3277 (Linking) VI - 20 IP - 3 DP - 2020 Jun TI - Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial. PG - 283-293 LID - 10.1007/s40256-019-00381-1 [doi] AB - BACKGROUND: Metformin is the most widely used oral antihyperglycemic agent for patients with type 2 diabetes mellitus (T2DM). Despite the possible benefits of metformin on diabetes mellitus (DM) and heart failure (HF), acute or unstable HF remains a precaution for its use. OBJECTIVE: The aim of the present prospective randomized controlled trial was to assess whether metformin treatment has beneficial effects on patients with T2DM with hypertension without overt HF. METHODS: A total of 164 patients (92 males, 72 females; median age 66 years) were included in this study. Patients with T2DM with a history of hypertension were randomized 1:1 to treatment for 1 year with either metformin (metformin-treated group) or other hypoglycemic agents (control group). The primary endpoints were changes in brain natriuretic peptide (BNP) levels, left ventricular (LV) mass index, and indicators of LV diastolic function. We also evaluated changes in both clinical findings and blood laboratory examination data. RESULTS: We observed no significant changes between baseline and 1-year post-treatment in LV mass index, BNP levels, or E/e' (early diastolic transmitral flow velocity/early diastolic mitral annular velocity; an indicator of LV diastolic function) in either the metformin-treated (n = 83) or the control (n = 81) groups. The metformin-treated group had a significant reduction of body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C), but the control group did not. We determined that renal function, including serum creatinine and estimated glomerular filtration rate, deteriorated significantly in the control group but not in the metformin-treated group. CONCLUSION: LV mass and diastolic function were not affected after 1 year of metformin treatment in patients with T2DM. However, we observed benefits in terms of reductions in both BMI and LDL-C levels and preservation of renal function. TRIAL REGISTRATION: UMIN000006504. Registered 7 October 2011. FAU - Ono, Koh AU - Ono K AUID- ORCID: 0000-0002-4163-980X AD - Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. kohono@kuhp.kyoto-u.ac.jp. AD - Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. kohono@kuhp.kyoto-u.ac.jp. FAU - Wada, Hiromichi AU - Wada H AD - Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. FAU - Satoh-Asahara, Noriko AU - Satoh-Asahara N AD - Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. FAU - Inoue, Hitoki AU - Inoue H AD - Department of Cardiology, National Hospital Organization Hokkaido Cancer Center, 2-3-54, Kikusuishijyo, Shiraishi-ku, Sapporo, Hokkaido, 003-0804, Japan. FAU - Uehara, Keita AU - Uehara K AD - Department of Gastroenterology, National Hospital Organization Tochigi Medical Center, 1-10-37, Nakatomatsuri, Utsunomiya, Tochigi, 3208580, Japan. FAU - Funada, Junichi AU - Funada J AD - Department of Cardiology, National Hospital Organization Ehime Medical Center, 366 Yokogawara, Toon, Ehime, 791-0281, Japan. FAU - Ogo, Atsushi AU - Ogo A AD - Department of Metabolism and Endocrinology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. FAU - Horie, Takahiro AU - Horie T AD - Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. FAU - Fujita, Masatoshi AU - Fujita M AD - Department of Cardiovascular Medicine, Uji Hospital, Uji, Kyoto, Japan. FAU - Shimatsu, Akira AU - Shimatsu A AD - Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. FAU - Hasegawa, Koji AU - Hasegawa K AD - Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. CN - ABLE-MET Investigators LA - eng PT - Clinical Trial, Phase IV PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - New Zealand TA - Am J Cardiovasc Drugs JT - American journal of cardiovascular drugs : drugs, devices, and other interventions JID - 100967755 RN - 0 (Cholesterol, LDL) RN - 0 (Hypoglycemic Agents) RN - 114471-18-0 (Natriuretic Peptide, Brain) RN - 9100L32L2N (Metformin) SB - IM MH - Aged MH - Body Mass Index MH - Cholesterol, LDL/blood MH - *Diabetes Mellitus, Type 2/complications/drug therapy/physiopathology MH - Female MH - *Heart Ventricles/pathology/physiopathology MH - Humans MH - *Hypertension/complications/diagnosis/metabolism MH - Hypoglycemic Agents/administration & dosage/pharmacokinetics MH - Male MH - *Metformin/administration & dosage/pharmacokinetics MH - Natriuretic Peptide, Brain/blood MH - Organ Size/drug effects MH - Treatment Outcome MH - Ventricular Function, Left/*drug effects PMC - PMC7266803 COIS- Koh Ono, Hiromichi Wada, Noriko Satoh-Asahara, Hitoki Inoue, Keita Uehara, Junichi Funada, Atsushi Ogo, Takahiro Horie, Masatoshi Fujita, Akira Shimatsu, and Koji Hasegawa have no conflicts of interest that are directly relevant to the content of this article. EDAT- 2019/11/14 06:00 MHDA- 2021/03/23 06:00 PMCR- 2019/11/13 CRDT- 2019/11/14 06:00 PHST- 2019/11/14 06:00 [pubmed] PHST- 2021/03/23 06:00 [medline] PHST- 2019/11/14 06:00 [entrez] PHST- 2019/11/13 00:00 [pmc-release] AID - 10.1007/s40256-019-00381-1 [pii] AID - 381 [pii] AID - 10.1007/s40256-019-00381-1 [doi] PST - ppublish SO - Am J Cardiovasc Drugs. 2020 Jun;20(3):283-293. doi: 10.1007/s40256-019-00381-1.